Interview Transcript

This is a snippet of the transcript, sign up to read more.

That sounds about right. I believe CellaVision themselves mentioned something like 15% to 20%. So 15% seems fair.

Yes, but you'll find other places, like Moffitt Cancer Center here in Florida, where the slide review rate is much higher due to the nature of their patients. At a place like Tampa General Hospital, which is a general hospital, they probably have about a 15% review rate. However, that review rate can vary. The review itself could be a platelet morphology review, a red cell morphology review, or a 100% slide count review. So that 15% will have a breakdown of different types of reviews.

This is a snippet of the transcript, sign up to read more.

Just a basic question. Who are they the main providers of cell counters for that initial white blood cell counts or red blood cell count. Beckman Coulter obviously has a few models, Sysmex has a few. How do you think who are the main providers and how do you think about them in terms of market share?

Sysmex definitely has the largest market share, probably over 80% in the US. It's really high. Then you have Beckman Coulter. But it depends on the market too. In the non-acute market, Beckman Coulter has a higher percentage of market share. In the government space, Sysmex has about 80%. In the hospital space, Sysmex also has about 80%, while Beckman Coulter has around 17%, with the small remaining percentage being Siemens.

This is a snippet of the transcript, sign up to read more.

Sign up to test our content quality with a free sample of 50+ interviews